[1] Hang CH. Zhongguo Weiqin Shenjing Waike Zazhi. 2011; 16(9):429-432.杭春华.脑胶质瘤的治疗进展[J].中国微侵袭神经外科杂志,2011, 16(9):429-432.[2] Reya T,Morrison S J,Clarke M F,et al. Stem cells,cancer stem cells. Nature.2001,414(6859):105-111.[3] Huang XD, Sun FF, Ye XQ. Shengming de Huaxue. 2011; 31(4):502-505.黄学德,孙芬芬,叶小群.肿瘤干细胞与肿瘤转移[J].生命的化学, 2011, 31(4):502-505.[4] Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors.Cancer Res. 2003; 63(18):5821-5828.[5] Cheshier SH, Kalani MY, Lim M, et al .A neurosurgeon's guide to stem cells, cancer stem cells, and brain tumor stem cells. Neurosurgery.2009;65(2):237-250.[6] Cheng JX, Liu BL, Zhang X.How powerful is CD133 as a cancer stem cell marker in brain tumors? Cancer Treat Rev. 2009;35(5):403-408.[7] Zhao ZF, Yang B, Guan FX, et al. Zhengzhou Daxue Xuebao (Yixueban). 2007;42(2):365-366.赵中甫,杨波,关方霞,等.脑胶质瘤不同位点肿瘤干细胞的特性分析[J].郑州大学学报:医学版,2007,42(2),365-366.[8] Ke J, He J. Xiandai Yixue. 2009;37(3):192-195.柯金,何杰.脑肿瘤干细胞放射敏感性的实验研究[J].现代医学, 2009,37(3):192-195.[9] Li ZM, Cui YQ. Xiandai Zhongliu Yixue. 2006;14(1):12-13.李珠明,崔玉琴.三维适形放疗与立体定向放射外科治疗脑胶质瘤初步临床分析[J].现代肿瘤医学,2006,14(1):12-13.[10] Wang JJ, Wang G, Zhou ZM, et al. Aizheng Jinzhan. 2011; 9(1):63-67.王俊杰,王刚,周章明,等.神经胶质瘤的治疗研究进展[J].癌症进展,2011,9(1):63-67.[11] Pirtoli L,Rubino G, Marsili S, et al. Three-dimensional conformal radiotherapy, temozolomide chemotherapy, and high-dose fracdonated stereotactic boost in a protocol-driven, postoperative treatment schedule for high-grade gliomas. Tumori,2009,95:329-337.[12] Louis DN, Ohgaki H, Wiestler OD,et al.The 2007 WHO classification of tumours of the central nervous system.Acta Neuropathol.2007;114(2):97-109.[13] Ji XT, Zhang X, Fei Z, et al. Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu. 2007;11(24):4690-4692.姬西团,章翔,费舟,等.人胚胎神经干细胞体外条件下对胶质瘤细胞的趋向性特点[J].中国组织工程研究与临床康复,2007, 11(24) 4690-4692.[14] Zhang L, Li XL. Zhongguo Xiandai Yixue Zazhi. 2012;22(20): 52-55.张蕾,李晓莉. 神经干细胞的分离培养和鉴定及体外长期培养[J]. 中国现代医学杂志,2012,22(20):52-55.[15] Yuan X,Curtin J,Xiong Y,et al.Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene. 2004;23(58): 9392-9400.[16] Duan XB, Guan FX, Deng XH, et al. Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu. 2011;15(23): 4215-4219.段小兵,关方霞,邓晓辉,等.海洋单细胞海藻体外对人脑胶质瘤干细胞生物学活性的影响[J].中国组织工程研究与临床康复,2011, 15(23):4215-4219.[17] Kong BH, Park NR, Shim JK, et al.Isolation of glioma cancer stem cells in relation to histological grades in glioma specimens. Childs Nerv Syst. 2012 Nov 10.[18] Warrier S, Pavanram P, Raina D, et al.Study of chemoresistant CD133+ cancer stem cells from human glioblastoma cell line U138MG using multiple assays. Cell Biol Int. 2012;36(12):1137-1143.[19] Azari H, Millette S, Ansari S, et al.Isolation and expansion of human glioblastoma multiforme tumor cells using the neurosphere assay. J Vis Exp. 2011;30(56):3791-3633.[20] Liu YG, Yang ZY, Wang TH. Sichuan Jiepouxue Zazhi. 2012; 20(3):1-4,8.刘永贵,杨智勇,王廷华.胶质瘤细胞及其干细胞的放疗敏感性差异[J]. 四川解剖学杂志,2012,20(3):1-4,8.[21] Lu HM, Qiang YZ, Shi Q, et al. Fushe Fanghu. 2001;21(6): 349-353.卢红梅,强亦忠,施勤,等.p53基因状态对人卵巢癌细胞辐射敏感性的影响[J].辐射防护,2001,21(6):349-353.[22] Wang XX, Liu JP. Zhongguo Zuzhi Gongcheng Yanjiu. 2012; 16(14):2637-2640.王欣欣,刘季平.脑肿瘤干细胞的研究现状[J].中国组织工程研究, 2012,16(14):2637-2640. [23] Zhou CH. Zhongliu Yanjiu yu Linchuang. 2006;18(4):280-282.周陈华.脑胶质瘤的放射治疗进展[J].肿瘤研究与临床, 2006, 18(4): 280-282.[24] Xiong XH. Fujin Yiyao Zazhi. 2011;33(4):145-147.熊学辉.神经胶质瘤治疗方法进展[J].福津医药杂志,2011, 33(4): 145-147.[25] Kovács A, Tóth L, Glavák C,et al.Integrating functional MRI information into conventional 3D radiotherapy planning of CNS tumors. Is it worth it? J Neurooncol. 2011;105(3): 629-637.[26] Grossman SA,Batara JF.Current management of glioblastoma multiforme.Semin Oncol.2004;31(5):635-644.[27] Tanaka S, Louis DN, Curry WT, et al. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol. 2012.[28] Reni M,Cozzarini C,Panucci MG,et al.Irradiation fields and doses in glioblast- oma multiforme:are current standards adequate.Tumori.2001;87(2):85-90.[29] Nieder C,Andratschke N,Wiedenmann N,et al. Radiotherapy for high-grade gliomas. Does altered fractionation improve the outcome?.Strahlenther Onkol.2004;180(7):401-407.[30] Lee DS, Yu M, Jang HS,et al.Radiation-induced brain injury: retrospective analysis of twelve pathologically proven cases. Radiat Oncol J. 2011;29(3):147-155.[31] Grosu AL,Weber W,Feldmann HJ,et al.First experience with I-123-alpha- methyl-tyrosine spect in the 3-D radiation treatment planning of brain gliomas.Int J Radiat Oncol Biol Phys.2000;47(2):517-526.[32] Tralins KS,Douglas JG,Stelzer KJ,et al.Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation.J Nucl Med.2002;43(12):1667- 1673.[33] Paldino MJ, Wong TZ, Reardon DA, et al.Prognostic significance of parameters derived from co-registered 18F-fluorodeoxyglucose PET and contrast-enhanced MRI in patients with high-grade glioma. Br J Radiol. 2011;84(1000): 327-333. [34] Iliadis G, Kotoula V, Chatzisotiriou A, et al. Volumetric and MGMT parameters in glioblastoma patients: survival analysis. BMC Cancer. 2012 Jan 3;12:3.[35] Tian Y Guan FX,Hu X, et al. Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu. 2010,14(10):1721-1728.田毅,关方霞,胡祥,等.人脐带沃顿胶间充质干细胞与脑肿瘤干细胞的共培养[J].中国组织工程研究与临床康复,2010,14(10): 1721-1728. |